| INTRODUCTION
The discovery of Helicobacter pylori (H. pylori) has revolutionised pathophysiology and clinical approach to upper gastrointestinal disease. 1 H. pylori causes peptic ulcers, gastric mucosa associated lymphoid tissue lymphoma, and gastric cancer. 1 Standard treatments for H. pylori infection rely on antimicrobials (eg, amoxicillin, clarithromycin, metronidazole, levofloxacin or bismuth compounds) in combination with gastric acid inhibitors. [2] [3] [4] [5] Primary resistance can significantly impair the efficacy of eradication regimens, especially those including macrolides (like clarithromycin). 3, 4, 6 The World Health Organization has recently published its first ever list of antibiotic-resistant "priority pathogens", a catalogue of 12 families of bacteria that pose the greatest threat to human health. 7 They indicated three priorities (ie, critical, high and medium), and clarithromycinresistant H. pylori was categorised as a high-priority bacterium in the same tier as vancomycin-intermediate or resistant, and methicillinresistant Staphylococcus aureus. 7 Resistance to fluoroquinolones (such as levofloxacin) can also impair the efficacy of eradication regimens. 3, 4, 6 However, resistance to nitroimidazole could be partially overcome in vivo. 8 Therapies for H. pylori are based on antimicrobial agents also used for other infectious diseases. [3] [4] [5] Since antibiotic resistance develops continuously, it is mandatory to perform periodic prevalence assessment [9] [10] [11] [12] to guide clinicians in selecting the most appropriate therapy in their setting, and also obtaining valuable indirect information concerning the use of the antimicrobial agents tested in the community. [13] [14] [15] Sequential therapy, an eradication regimen developed and widely studied in Italy, 2, 16 was initially reported to be very effective in patients harbouring strains resistant to clarithromycin or/and metronidazole, 16 albeit this has been questioned by subsequent papers, and derived meta-analyses. 2, 17 However, the number of patients with resistant strains evaluated in published studies was generally very small.
The aim of our study was therefore threefold: (1) to evaluate trends in the prevalence of primary resistance to three antimicrobial agents (namely clarithromycin, metronidazole and levofloxacin), most commonly used in the eradication regimens, over a 5 year period; (2) to assess the effectiveness of sequential therapy on a large number of strains resistant to clarithromycin or/and metronidazole, and, finally, (3) to identify a minimum number of patients to study to get a reliable estimate of effectiveness of a given treatment (namely sequential therapy) in patients harbouring resistant strains.
2 | ME TH ODS To identify the optimum number of strains required to yield precise estimate of eradication rates, a bootstrap analysis was firstly performed. 31 Patients who completed the follow-up were subgrouped according to the pattern of antimicrobial susceptibility/resistance as: (1) 
| RESULTS
The study flow diagram of the study is shown in Figure S1 . Table S1 , the clinical characteristics of the patients included in the analysis are shown. For all variables considered in Table S1 , there were no significant differences among the years considered (v 2 test for trend: P < 0.05). Of the 1325 patients, 1185
received sequential therapy, 65 were lost to follow-up, and 1120
were followed up.
| Pattern of susceptibility and resistance considering the antimicrobial agents tested
When all the three antimicrobial agents were considered together ( Figure S2) concentration equal to 0.38 lg/mL, and 69.84% (95% CI: 57.6-79.8) a value of minimal inhibitory concentration equal to 0.50 lg/mL.
The results of univariate and multivariate regression analysis are shown in Table S3 . The multivariate analysis showed that the risk of carrying strains resistant to clarithromycin increased significantly only over the years (OR: 1.15; 95% CI: 1.08-1.23; P < 0.0001; Figure 3A ). Figure 2 ). The distribution of minimal inhibitory concentration for metronidazole is shown in Figure S4 .
The results of univariate and multivariate regression analysis are shown in Table S4 . The multivariate analysis showed that the risk of carrying strains resistant to metronidazole increased significantly over the years (OR: 1.11; 95% CI: 1.04-1.19; P = 0.002; Figure 3B ).
Furthermore, the risk was also associated to female sex (OR: 2.13; Figure 2 ). The distribution of minimal inhibitory concentration for levofloxacin is depicted in Figure S5 . Table S5 . The multivariate analysis showed that the risk of carrying strains resistant to levofloxacin increased significantly only over the years (OR: 1.16; 95% CI: 1.08-1.25; P < 0.0001; Figure 3C ).
| Trend of antimicrobial resistance between 2001 and 2015
The statistically significant increase in resistance rates for all the antimicrobial agents, tested between 2010 and 2015, was also corroborated from the retrospective analysis of historical data from our centre, which were previously included in published papers. 16, 33 As shown in Figure 4 , there was significant increase in primary resistance over time for clarithromycin (v 2 test for trend: P < 0.0001), metronidazole (v 2 test for trend: P < 0.0091), and levofloxacin (v 2 test for trend: P < 0.0019).
| Eradication rate in followed up patients
Of the 1325 patients evaluated, 1185 received sequential therapy. Table 1 -show that the higher the eradication rate in the parent population, the lower the minimum number of strains required to evaluate, at any given power. The estimated minimum sample needed to give consistent results for theoretical eradication rates ranging from 50% to 95% was also calculated and the results are depicted in Figure 6 . These data show that the number of strains (patients) to be evaluated increases as the success of a given therapy decreases, corroborating the data of the bootstrap analysis. For therapies whose eradication rates range between 75% and 85% (an average cure rate achieved by several regimens in the real word 2 ), it could be estimated that a sample size ranging between 98 and 144 patients should be enrolled to get a reliable and consistent estimate of eradication rate.
| DISCUSSION
There are several factors that can influence the efficacy of an anti-H. pylori therapy. 34 Despite drug, dose, formulation, duration of treatment and selection of medications able to increase the gastric pH, are all important factors, resistance to antimicrobials remains the most critical one 3, 4, 34 and is mainly responsible for the decreasing eradication rates. [3] [4] [5] One of the main aims of this study was to evaluate the prevalence of primary resistance to three antimicrobial agents (namely clarithromycin, metronidazole and levofloxacin) most commonly used in the eradication regimens, over a 5 years' time frame. When the three antimicrobial agents were considered together, more than 60% of strains were resistant to at least one of them. If only clarithromycin and metronidazole were considered, 55% of strains were resistant to at least one of these two agents.
Furthermore, the rate of primary resistance to clarithromycin, Changes in prevalence of primary resistance mainly depend on the antibiotic consumption in a given geographic area. 6, 13 In North America, a multicentre study 6 reported a resistance rate of 10.2% to clarithromycin and 29.1% to metronidazole. An additional, cross-sectional study 35 (including nearly 90.2% men), found that the prevalence of resistance to clarithromycin was 16.4%, to metronidazole was 20.3%, and to levofloxacin 31.3%. According to a systematic review, 36 these figures in South America are 12%, 53% and 15%
respectively. In Japan, an increase in resistance to clarithromycin from 18.9% to 27.7% between 2002 and 2005 was reported, 37 while resistance to metronidazole remained fairly consistent (ranging from 3.3% to 5.3%).
In Europe, 11 resistance rates were found to be 17.5% to clarithromycin, 14.1% to levofloxacin and 34.9% to metronidazole.
Resistance rate to clarithromycin and levofloxacin were significantly higher in Southern than in Northern Europe. 11 In our study, resistance rates to clarithromycin and levofloxacin were clearly higher than those reported by the European survey. Second, the high primary resistance rate to levofloxacin, found in our region, does suggest that any levofloxacin-based regimen (be it triple or quadruple) should be used with caution.
Finally, trials assessing the efficacy of a H. pylori regimen, especially in na€ ıve patients, should always include susceptibility testing.
This approach has been advocated since 2001. 39 Data on efficacy or effectiveness of regimens without susceptibility testing do not allow results to be put in the right perspective: different treatments can have different performances in different areas, due to different primary resistance rates. 2 The other aim of our study was to evaluate the effectiveness of sequential therapy in patients harbouring strains resistant to clarithromycin or/and metronidazole. Our results show that this regimen is highly effective in patients harbouring strains clarithromycin resistant and metronidazole susceptible as well as clarithromycin susceptible and metronidazole resistant, with an eradication rate above the proposed cut-off ≥90%. 40 The effectiveness of sequential therapy in T A B L E 1 Power of each sample to detect the parent population eradication rate AE 1%, assuming a two-sided a-value of 0.05, according to the bootstraps analysis performed The major strength of our study is represented by the large number of resistant strains analysed. Usually, the interpretation of data concerning the efficacy or effectiveness of regimens in resistant strains is tricky due to the small samples assessed, and their wide confidence intervals, 42, 43 as shown in Figure 7 . This Figure depicts the eradication rates of the 10 studies, reported by Maastricht V/ Florence Consensus, 4 using 10-day sequential therapy in patients harbouring strains resistant to clarithromycin and metronidazole. It is apparent that the confidence intervals of six of 10 studies fall within the confidence interval calculated from our study. Indeed, with such small samples, a single patient moving from "eradicated" to "not eradicated" population would affect the effective eradication rate by (at least) 10%, more than enough to affect the clinical conclusions.
For this reason, the most important goal our study was to identify a minimum number of patients (with a particular resistance pattern) to study to have consistent and reliable data regarding the eradication rate. Our analyses show that the higher the eradication rate in the parent population, the lower the sample to evaluate, whatever the selected power is. Furthermore, since most therapies used for H. pylori treatment have an eradication rate ranging between 75% and 85%, a sample of patients between 98 and 144 should be enrolled to get a reliable and consistent estimate of eradication rate for each patter of resistance.
The above findings underline the importance of studies like our own, which-despite being non-randomised-allow to include a very large number of patients for each single pattern of resistance. On the other hand, a randomised study, specifically designed to evaluate the efficacy of a given eradication regimen in patients with single or dual antimicrobial resistance would be very challenging, long-lasting and costly.
This study presents some limitations. Data on previous exposure to antibiotics were not available. Our findings were also based on patients enrolled in a single referral centre, and therefore the study population may not adequately mirror the general population. 
